MTP-101C
PreclinicalSmall molecule
MTP-101C is one of 6 small molecule programs targeting Amyotrophic Lateral Sclerosis (ALS). It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Amyotrophic Lateral Sclerosis (ALS)
#DrugCompanyPhaseTrials
1Rilutek
AAzurity Pharmaceuticals
Phase 2
VHB937
NovartisPhase 2
Cromolyn Sodium
UUniversity of California, San Francisco
Phase 2
XT-150
XXalud Therapeutics, Inc.
Phase 1
NUZ-001
MMerit E. Cudkowicz, MD
Preclinical
MTP-101C
UUniversity of Minnesota
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MTP-101C. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Minnesota